• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

E-Z-EM introduces new bowel agent

Article

Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel,

Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel, inwhich the translucency of the intestine is maintained even throughmultiple organ layers. Entero Vu allows radiologists to obtaina clear study of the entire small bowel, according to the company.

E-Z-EM claims that Entero Vu offers clearer images than small-bowelstudies using conventional oral contrast media, which often lackdefinition and detail because of the high density of the media.Because it is administered orally, Entero Vu is also easier tohandle than another small-bowel imaging procedure, enteroclysis,in which contrast is directly infused into the small intestinevia a catheter.

E-Z-EM has set a list price of $198 for a box of Entero Vu, whichconsists of 12 doses.

Related Videos
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.